Back
Full-text
Journal article

Tools to study and target the Siglec-sialic acid axis in cancer.

  • Läubli H Laboratory for Cancer Immunotherapy, Department of Biomedicine, and Medical Oncology, Department of Internal Medicine, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland.
  • Kawanishi K Kidney and Vascular Pathology, University of Tsukuba, Ibaraki, Japan.
  • Vazhappilly CG Department of Biotechnology, American University of Ras Al Khaimah (AURAK), Ras Al Khaimah, 10021, UAE.
  • Matar R Department of Biotechnology, American University of Ras Al Khaimah (AURAK), Ras Al Khaimah, 10021, UAE.
  • Merheb M Department of Biotechnology, American University of Ras Al Khaimah (AURAK), Ras Al Khaimah, 10021, UAE.
  • Sarwar Siddiqui S Department of Biotechnology, American University of Ras Al Khaimah (AURAK), Ras Al Khaimah, 10021, UAE.
Show more…
  • 2020-11-30
Published in:
  • The FEBS journal. - 2020
Sialidase
Siglecs
blocking antibody
hypersialylation
mouse model
sialic acid
English Siglecs are widely expressed on leukocytes and bind to ubiquitously presented glycans containing sialic acids (sialoglycans). Most Siglecs carry an immunoreceptor tyrosine-based inhibition motif (ITIM) and elicit an inhibitory intracellular signal upon ligand binding. A few Siglec receptors can, however, recruit an immunoreceptor tyrosine-based activation motif (ITAM)-containing factors, which activate cells. The role of hypersialylation (the enhanced expression of sialolglycans) - in cancer progression has recently been explored. Mechanistic studies have shown that hypersialylation on cancer cells can engage inhibitory Siglecs on the surface of innate immune cells and induce immunosuppression. These recent studies strongly suggest that the Siglec-sialic acid axis can act as a potential target for cancer immunotherapy. Moreover, the use of new tools and techniques are facilitating these studies. In this review we summarise techniques used to study Siglecs, including different mouse models, monoclonal antibodies, Siglec fusion proteins and sialoglycan arrays. Furthermore, we discuss the recent major developments in the study of Siglecs in cancer immunosuppression, tools and techniques used in targeting the Siglec-sialic acid axis and the possibility of clinical intervention.
Language
  • English
Open access status
bronze
Identifiers
Persistent URL
https://sonar.ch/global/documents/207184
Statistics
Document views: 30 File downloads:
  • fulltext.pdf: 0